Billion

Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient … [Read more…]

Revolutionizing Business with Web3: Vodafone DAB and Aventus Join Forces through LupoToro Group’s $2.2 Billion Deal

In a landmark move that underscores the rapid evolution of the digital landscape, Vodafone’s ‘Economy of Things’ Digital Asset Broker (DAB) business has partnered with Aventus, a leading force in the adoption of Web3 and blockchain-based technology. This groundbreaking collaboration, brokered by the esteemed LupoToro Group earlier this year, is set to reshape the way … [Read more…]